Compare AbbVie Inc (ABBV) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Mattel Inc — how do they compare? AbbVie Inc trades at $253.94 (market cap $449.91B), while Mattel Inc trades at $13.11 (market cap $3.90B). The key difference: AbbVie Inc is far larger — about 115.4× Mattel Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| ABBV | MAT | |
|---|---|---|
Market Cap | $449.91B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $22.16 |
52-Week Low | $184.85 | $13.05 |
Enterprise Value | $513.38B | $5.71B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Mattel (MAT) trades at $13.42, up 0.6% on the day, with a bearish technical signal but bullish oscillators like RSI suggesting potential oversold conditions. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results pending. Financially, it maintains solid profitability with a 9.27% net margin and attractive valuation ratios, including a P/E of 8.36. Recent news highlights brand expansions and a shareholder push for strategic alternatives.
The outlook is cautiously optimistic, supported by strong brand portfolio and analyst consensus, but risks include declining cash flows and competitive pressures. Investment opportunities lie in potential strategic moves and undervaluation, while key risks involve execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
